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Available online 26 November 2015The Genea052 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, through ICM outgrowth on inactivated human feeders. The line showed pluripotent cell morphology
and genomic analysis veriﬁed a 46, XY karyotype and male allele pattern through CGH and STR analysis.
Pluripotency of Genea052 was demonstrated with 85% of cells expressing Nanog, 87% Oct4, 60% Tra1-60 and
97% SSEA4, a PluriTest Pluripotency score of 27.21, Novelty score of 1.2 and tri-lineage teratoma formation.
The cell line was negative forMycoplasma and any visible contamination.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Resource tableame of stem cell line Genea052 (alternate ID: SIVF052)
stitution Genea biocells
erson who created resource Omar Chami
ontact person and email biljana.dumevska@geneabiocells.com
ate archived/stock date November, 2009
rigin Human embryos
pe of resource Derived human embryonic stem cell line
b-type Human pluripotent cell line
ey marker expression Nanog, Oct4, Tra1-60, and SSEA4
uthentication Identity and purity of cell line conﬁrmed
(Figs. 1–5 below)
nk to related literature (direct
URL links and full references)
formation in public databases National Institutes of Health (NIH) registered
NIHhESC-13-0234
UK Stem Cell Bank (UKSCB) registered
SCSC14-36thical approval Obtained from the Genea Ethics Committee
on 21 February 2001 under the Australian
National Health and Medical Research Council
(NHMRC) licence 309703Resource detailsate of derivation October 2009
aryotype 46, XY — no abnormalities detected
x Male
luripotent Yes — by Nanog, Oct4, Tra1-60, and SSEA4 staining,
tri-lineage teratoma formation and PluriTest
isease status Unaffected
erility The cell line is tested and found negative for
Mycoplasma and any visible contamination
bling lines available NoSi. This is an open access article under1. Materials and methods
1.1. Cell line derivation
20%KSRmedium (Amit et al., 2000)was conditioned by culturewith
high density mitotically inactivated feeders (72,000 cells/cm2) for 24 h
@ 37° 5% CO2 5% O2. The medium is collected and every second day
for a period of 2 weeks. Medium from the 2 weeks is combined. The
zona pellucida of a blastocyst-stage human embryo was manually re-
moved using a small blade. The embryo was bisected and plated onto
human collagen type I (coated at 10 ng/mL Millipore #CC050) in a 1:1
mix of 20% Knock out serum in standard hESC culture medium (Amit
et al., 2000) and conditioned media, plus 50 ng/mL Fgf2 added fresh.
CGH, karyotyping and STR proﬁling were performed at the ﬁrst
cryobanking step from ICMoutgrowthsmaintained on feeders. Alkaline
phosphatase staining was performed on feeders. Cells were then enzy-
matically passaged as single cells in M2 pluripotent cell maintenance
medium (Genea Biocells) and genetic analysis repeated, immunoﬂuo-
rescent pluripotent marker staining, PluriTest, teratoma and sterility
testing performed.
1.2. Genetic analysis
1. Comparative genomic hybridisation (CGH) based chromosomal
analysis: Passage 9 (7 on feeders, 2 enzymatic); CGH was used to
screen targeted regions of the genome for gains and losses associated
with chromosomal imbalances such as aneuploidy, deletions and du-
plications. CGH was performed using SurePrint G3 microarrays
(8 × 60 K format) which were scanned with the Agilent Scanner C
and analysed using Genomic Workbench Standard Edition 5.0 soft-
ware (Agilent Technologies).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Brightﬁeld morphology of Genea052 on human inactivated feeders.
Table 1
CGH array summary.
Parameter Result
Sample name Genea052p9_2
Date reported 30th May 2014
Hybridisation balance A balanced hybridisation was observed for all
chromosomes, relative to reference DNA
Copy number change Loss of 875 kb at chromosome region 4p12 — not
clinically relevant
Interpretation Male cell line — no abnormalities detected
328 B. Dumevska et al. / Stem Cell Research 16 (2016) 327–3302. DNA proﬁling: Passage 4; DNA ‘ﬁngerprinting’ was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the
cell lines. https://www.thermoﬁsher.com/order/catalog/product/
4322288
1.3. Pluripotency assessment
1. Immunoﬂuorescence: Passage 9 (7 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560,483 1:200;
Oct4 #560,217 1:150: Tra1-60 #560,121 1:150; SSEA4 #560,308
1:200 (all BD Pharmingen:). Images were acquired with an IN
Cell Analyser 6000 and quantiﬁed using In Cell Developer Software
(GE).
2. PluriTest: Passage 9 (7 on feeders, 2 enzymatic); RNA was collected
and subjected to a PluriTest, a bioinformatic assay of pluripotency
in human cells based on gene expression proﬁles (Müller et al.,
2012)
3. Teratoma formation: Passage p7; stem cells were received one day
prior to injection. On the day of injection cells were harvested by
manual scraping, washed and resuspended in DMEM/20% KSR for in-
jection. In both experiments, mice were anaesthetized before intra-
muscular injection of cells into the left inner thigh muscle of the
hind leg. Approximately 1–2 × 106 cells (1xT25) in 50 μL were
injected per mouse at one site only. Resultant teratomas were ex-
cised, ﬁxed, sectioned and stained for assessment of tissues from
each of the embryonic germ layers.
1.4. Sterility testing
1. Mycoplasma: Passage 2; testing was performed at the Victorian
Infectious Diseases Reference Laboratory using Mycoplasma Genus
PCR
2. Microbial contamination: testingwas performed in conjunctionwith
our QC measures. Cells were thawed and cultured in 7 mL antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C.
A clear solution at ~48–72 h indicated lack of bacterial, fungal
or yeast contamination. Clarity of the solution was assessed by Cell
Production Team.
2. Veriﬁcation and authentication
2.1. Ethics/consents
Ethics approval for the project (‘development of human embryonic
stem cells from excess ART embryos’) was obtained from the Genea
Ethics Committee on 21 February 2001. Excess ART embryos were
fully consented for stem cell derivation by all responsible people
through an informed consent process (signed de-identiﬁed consent
form can be provided upon request). Donors have received no pay-
ment or ﬁnancial beneﬁts for their donation. Genea052 has been de-
rived from a donated, fully commercially consented human embryo,
originally created by assisted reproduction technology (ART) for the
purpose of procreation, under Australian National Health and Medical
Research Council (NHMRC) licence 309703. This licence was issued
to GENEA on 16 April 2004. More information about the licence
can be obtained from the NHMRC webpage at http://www.nhmrc.
gov.au/health-ethics/human-embryos-and-cloning/database-licences-
authorising-use-excess-art-embryos.
2.2. Morphology
The derived stem cell line, Genea052, morphologically displays ad-
herent monolayer of compact cells in well-deﬁned colonies with high
nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1).2.3. Genetic analysis
The cell line has been tested by CGH (Table 1, Supplementary Fig. 1),
which demonstrated 46, XY karyotype, consistent with original deriva-
tion. Analysis of STR markers showed allele pattern consistent with
male genotype (Fig. 2, Supplementary Fig. 2).
2.4. Disease status
Unaffected.
2.5. Pluripotency
GENEA052 is pluripotent by;1. Immunoﬂuorescence with 85% Nanog positive, 87% Oct4 positive,
60% Tra1-60 positive, and 97% SSEA4 positive (Fig. 3A, quantiﬁed
in 3B).
2. PluriTest with a 27.21 Pluripotency score and 1.2 Novelty score
(Fig. 4).
3. Teratoma formation which contained tissues derived from each of
the embryonic germ layers: endoderm, mesoderm, and ectoderm
(Fig. 5).2.6. Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 3).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2015.11.014.
Fig. 2. STR proﬁle.
Fig. 3. Percentage of cells expressing SSEA4, Nanog, Oct3/4 and Tra1/60 as detected by immunoﬂuorescence.
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Fig. 4. PluriTest.
Fig. 5. Tri lineage teratoma formation.
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